Oncologia Medica 1, Istituto Oncologico Veneto (IOV)-IRCCS, Via Gattamelata, Padova, Italy.
Am J Clin Oncol. 2011 Jun;34(3):305-8. doi: 10.1097/COC.0b013e3181e1cb22.
This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel.
We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008.
A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m(2), respectively, over 2 day, every 4 weeks.
Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.
本回顾性分析旨在描述在接受卡铂和紫杉醇一线化疗时发生骨髓抑制（主要为中性粒细胞减少症）的复发性卵巢癌患者中，使用聚乙二醇脂质体阿霉素（PLD）和奥沙利铂治疗的安全性概况。
我们回顾了 2002 年至 2008 年间在威尼托肿瘤研究所（IOV）/帕多瓦大学接受 PLD/Oxaliplatin 治疗的复发性卵巢癌患者的病历。
选择了一组在接受卡铂/紫杉醇一线化疗时出现 3 级至 4 级骨髓抑制和其他毒性的 16 例患者进行这项回顾性研究。患者在接受卡铂和紫杉醇的一线化疗时主要发生 3 级至 4 级中性粒细胞减少症和 1 级至 3 级血小板减少症等主要毒性。在复发或疾病进展后，PLD/奥沙利铂化疗以 30 至 35 和 70mg/m2 的剂量，分别在 2 天内，每 4 周一次。
PLD/奥沙利铂治疗可完全缓解和稳定骨髓抑制，且无过敏反应。估计中位总生存期为 51.2 个月。PLD/奥沙利铂化疗未显示血液学毒性，并且在这组预处理虚弱的患者中是可行和有效的。
